Summary
The treatment of solid tumours with high-dose chemotherapy using alkylating agents either as single agents or in combination schedules has received increasing attention from clinical investigators in recent years. This has frequently been given in association with autologous bone marrow support, a technique which appears to ameliorate myelosuppression that might otherwise be dose-limiting, and which thus may allow dose escalation into a range previously not reached. Despite this ability, and in spite of much experimental evidence from drug-sensitive animal tumours that increasing doses result in increased response rates, no major impact has yet been made in the therapy of solid tumours using this form of therapy. In addition, the use of high-dose schedules has seen the emergence of extramedullary manifestations of drug toxicity which were not encountered at conventional doses.
Nevertheless, there are some encouraging data from reports in certain tumours, including small cell lung cancer, testicular cancer, ovarian cancer, and lymphoma, and further studies are clearly indicated. These should probably be restricted to certain drug-sensitive tumours, and should include an examination of the role of high-dose chemotherapy as consolidation treatment, following conventional induction therapy for selected tumour types.
This form of treatment may yet provide an important contribution to the control of human solid tumours, but much further work, probably with combination drug schedules, is required.
Similar content being viewed by others
References
Appelbaum FR, Strauchen JA, Graw RG, Savage DD, Kent KM, Ferrans VJ, Herzig GP (1976) Acute lethal carditis caused by high-dose combination chemotherapy. Lancet I:58
Appelbaum FR, Deisseroth AB, Graw RG (1978) Prolonged complete remission followed high dose chemotherapy of Burkitt's lymphoma in relapse. Cancer 41:1059
Ariel IM, Pack GT (1962) Treatment of disseminated melanoma with phenylalanine mustard (melphalan) and autogenous bone marrow transplants. Surgery 51:583
Banham S, Burnett A, Stevenson R, Cunningham D, Kaye S, Ahmedzai S, Soukop M (1982) Pilot study of combination chemotherapy with late dose intensification and autologous marrow rescue in small cel bronchial carcinoma. Br J Cancer 46:486
Bergsagel BE, Cowan VH, Hasselback R (1972) Plasma cell myeloma: response of melphalan-resistant patients to high-dose intermittent cyclophosphamide. Can Med Assoc J 107:851
Bleyer WA (1977) Methotrexate: Clinical pharmacology, current status and therapeutic guidelines. Cancer Treat Rev 4:87
Blijham G, Spitzer G, Litam J, Zander AR, Verma DS, Vellekoop L, Samuels ML, McCredie KB, Dicke KA (1981) The treatment of advanced testicular carcinoma with high-dose chemotherapy and autologous bone marrow support. Eur J Cancer 17:443
Bodey GP, Freireich EJ, McCredie KB, Smith TL, Gehan EA, Gutterman JU, Herjh EM (1981) Prolonged remissions in adults with acute leukaemia following late intensification chemotherapy and immunotherapy. Cancer 47:1937
Broder LE, Cohen MH, Selawry OS (1977) Treatment of bronchogenic carcinoma II Small cell. Cancer Treat Rev 4:219
Bryant BM, Jarman M, Ford HT, Smith IE (1980) Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma. Lancet II:657
Buckner CD, Rudolph RH, Fefer A, Clift RA, Epstein RB, Funk DD, Neiman PF, Slighter SJ, Storb R, Thomas ED (1972) High-dose cyclophosphamide therapy for malignant disease. Cancer 29:357
Buckner CD, Briggs R, Clift RA, Fefer A, Funk DD, Glucksberg H, Neiman PE, Storb E, Thomas ED (1974) Intermittent high-dose cyclophosphamide treatment of stage III ovarian carcinoma. Cancer Chemother Rep 58:697
Cohen MH, Creaven PJ, Fossieck JR, Broder LE, Selawry OS, Johnston AV, Williams CL, Minna JD (1977) Intensive chemotherapy of small cell bronchogenic carcinoma. Cancer Treat Rep 61:349
Cornbleet MA, Corringham RET, Prentice HG, Boesen EM, McElwain TJ (1981) Treatment of Ewing's sarcoma with high-dose melphalan and autologous bone marrow transplantation. Cancer Treat Rep 65:241
Creech RH, Catalano RB, Mastrangelo MJ, Engstrom PF (1975) An effective low-dose intermittent cyclophosphamide, methotrexate and 5-fluorouracil treatment regimen for metastatic breast cancer. Cancer 35:1101
Ekert H, Ellis WM, Waters KD, Tauro GP (1982) Autologous bone marrow rescue in the treatment of advanced tumours of childhood. Cancer 49:603
Farha P, Spitzer G, Valdivieso M, Zander A, Verma D, Minnhaar G, Vellekoop L, Dicke K, Bodey G (1981) Treatment of small cell bronchogenic carcinoma with high-dose chemotherapy and autologous bone marrow transplantation. Proc Am Soc Clin Oncol 22:496
Fay JW, Phillips GL, Herzig GP, Herzig RH, Lazarus HM (1980) Treatment of neoplastic disease of the central nervous system with high-dose BCNU and autologous marrow transplantation. Proc Am Soc Clin Oncol 21:353
Frei E, Canellos GP (1980) Dose: a critical factor in cancer chemotherapy. Am J Med 69:585
Gale RP, Graze PR, Wells J, Ho W, Cline MJ (1979) Autologous bone marrow transplantation in patients with cancer. Exp Haematol [Suppl 5] 7:351
Goldman KP (1963) High-dose mustine therapy for bronchial carcinoma. Br Med J I:312
Gorin NC, David R, Stachowiak J, Salmon CL, Petit JC, Parlier Y, Najman A, Duhamel G (1981) High-dose chemotherapy and autologous bone marrow transplantation in acute leukaemias, malignant lymphomas and solid tumors. Eur J Cancer 17:557
Gottdiener JS, Appelbaum FR, Ferrans VJ, Deisseroth A, Ziegler J (1981) Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med 141:758
Hande KR, McKay CM, Wedlund PJ, Noone RM, Shea WK, Fer MF, Greco FA, Wolff SN (1982) Clinical pharmacology of high dose VP16 213. Proc Am Assoc Cancer Res 23:131
Hedley DW, McElwain TJ, Millar JL, Gordon MY (1978) Acceleration of bone-marrow recovery by pre-treatment with cyclophosphamide in patients receiving high-dose melphalan. Lancet II:966
Hreshchyshyn MM (1973) Single-agent therapy in ovarian cancer; factors influencing response. Gynecol Oncol 1:220
Jones SE, Durie BGM, Salmon SE (1975) Combination chemotherapy with adriamycin and cyclophosphamide for advanced breast cancer. Cancer 36:90
Juma FD, Rogers HJ, Trounce JR (1980) The pharmacokinetics of cyclophosphamide, phosphoramide mustard and nornitrogen mustard studied by gas chromatography in patients receiving cyclophosphamide therapy. Br J Clin Pharmacol 10:327
Lazarus HM, Gottfried MR, Herzig RH, Phillips GL, Weiner RS, Sarna GP, Fay J, Wolff SN, Sudilovsky O, Gale RP, Herzig GP (1982) Veno-occlusive disease of the liver after high-dose mitomycin C therapy and autologous bone marrow transplantation. Cancer 49:1789
Levitt M, Mosher MB, De Conti RC, Farber LR, Skeel RT, Marsh JC, Mitchell MS, Papal RJ, Thomas ED, Bertino JR (1973) Improved therapeutic index of methotrexate with leucovorin rescue. Cancer Res 33:1729
Litam JP, Dail DH, Spitzer G, Vellekoop L, Verma DS, Zander AA, Dicke KA (1981) Early pulmonary toxicity after administration of high dose BCNU. Cancer Treat Rep 65:39
Lloyd RE, Jones SE, Salmon SE (1979) Comparative trial of low-dose adriamycin plus cyclophosphamide with or without additive hormone therapy in advanced breast cancer. Cancer 43:60
Lu C, Braine HG, Kaizer H, Tutschka PJ, Santos GW (1982) Phase I results of high-dose busulphan and cyclophosphamide with syngeneic or autologous bone marrow rescue. Proc Am Soc Clin Oncol 1:187
McElwain TJ, Hedley DW, Burton G, Clink HM, Gordon MY, Jarman M, Juttner CA, Millar JL, Milsted RAV, Prentice G, Smith IE, Spence D, Woods M (1979) Marrow autotransplantation accelerates haematological recovery in patients with malignant melanoma treated with high dose melphalan. Br J Cancer 40:72
Millar JL, Hodspith BN, McElwain TJ, Phelps TA (1978) Effect of high-dose melphalan on marrow and intestinal epithelium in mice pretreated with cyclophosphamide. Br J Cancer 38:137
Norton L, Simon R (1977) Tumor size, sensitivity to therapy and design of treatment schedules. Cancer Treat Rep 61:1307
Pegg DE, Humble JG, Newton KA (1962) The clinical application of bone marrow grafting. Br J Cancer 16:417
Phillips GL, Fay JW, Herzig GP, Napomberaja C, Wolff SN (1979) Intensive BCNU and autologous bone marrow transplantation therapy of refractory cancer: a preliminary report. Exp Haematol [Suppl 5] 7:372
Powis G, Ames MM, Kovach JS (1981) Dose-dependent pharmacokinetics and cancer chemotherapy. Cancer Chemother Pharmacol 6:1
Pritchard J, McElwain TJ, Graham-Pole (1982) High-dose melphalan with autologous marrow for treatment of advanced neuroblastoma. Br J Cancer 45:86
Rustin GJS, Cornbleet MA, Hedley DW, McElwain TJ (1981) High-dose melphalan in advanced malignant melanoma. Br J Cancer 43:719
Sarna GP, Champlin R, Wells J, Gale RP (1982) Phase I study of high-dose mitomycin C with autologous bone marrow support. Cancer Treat Rep 66:277
Schabel FM, Skipper HE, Trader MW, Laster WR, Corbett TH, Griswold DP (1980) Concepts for controlling drug-resistant tumour cells. In: Breast cancer. Experimental and clinical aspects. Pergamon Press, Oxford
Souhami RL, Harper PG, Linch D, Trask C, Goldstone AH, Tobias J, Spiro SG, Geddes DM, Richards JDM (1982) High-dose cyclophosphamide with autologous marrow transplantation as initial treatment of small cell carcinoma of the bronchus. Cancer Chemother Pharmacol 8:31
Spitzer G, Dicke KA, Litam J, Verma DS, Zander A, Lanzotti V, Valdivieso M, McCredie KB, Samuels ML (1980) High-dose combination chemotherapy with autologous bone marrow transplantation in adult solid tumors. Cancer 45:3075
Storb R, Prentice RL, Thomas ED (1977) Marrow transplantation for treatment of aplastic anaemia. N Engl J Med 296:61
Takvorian T, Parker LM, Hochberg FH, Zervas NP, Frei E, Canellos GP (1980) Single high doses of BCNU with autologous bone marrow (ABM): a phase I study. Proc Am Soc Clin Oncol 21:341
Tattersall MHN, Tobias JS (1976) How strong is the case for intensive cancer chemotherapy? Lancet II:1071
Thomas ED, Buckner CD, Clift RA, Fefer A, Johnson FL, Neiman PE, Sale GE, Sanders JE, Singer JW, Shulman H, Storb E, Weiden PL (1979) Marrow transplantation for acute non-lymphoblastic leukaemia in first remission. N Engl J Med 301:597
Tobias JS, Weiner RS, Griffiths CT, Richman CM, Parker LM, Yankee RA (1977) Cryopreserved autologous marrow infusion following high dose cancer chemotherapy. Eur J Cancer 13:269
Wolff SN, Fer MF, McKay C, Hainsworth J, Hande KR, Greco FA (1982) High-dose VP16 and autologous bone marrow transplantation for advanced malignancies — a phase I study. Proc Am Assoc Cancer Res 23:134
Young RC, Canellos GP, Chabner BA, Schein PS, Hubbard SP, DeVita VT (1974) Chemotherapy of advanced ovarian carcinoma: a prospective randomized comparison of phenylalanine mustard and high-dose cyclophosphamide. Gynecol Oncol 2:489
Zander AR, Spitzer G, Legha S, Dicke DA, Verma DS, Johnston DA, Vellekoop L, Beran M, Schell F, Minnhaar G, Blumenschein GR, Bodey GP (1982) High-dose AMSA and bone marrow rescue in patients with solid tumors. Cancer Treat Rep 66:385
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kaye, S.B. Intensive chemotherapy for solid tumours—Current clinical applications. Cancer Chemother. Pharmacol. 9, 127–133 (1982). https://doi.org/10.1007/BF00257740
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00257740